Moleculin Biotech, Inc.
Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Registro Oficial
Análisis de Calidad IA
Desglose de Puntuación de Confianza
Enlaces Rápidos
Destacados del sitio web
🌟 Empresas similares de confianza
Addex Therapeutics Ltd.
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Their pipeline includes compounds targeting post-stroke recovery, substance use disorder and chronic cough. The company utilizes its expertise in allosteric modulation for drug discovery.
SciSparc Ltd.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for the treatment of central nervous system disorders. Their pipeline includes drug candidates in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer’s Disease, Agitation, and Autism Spectrum Disorder. The company focuses on improving the lives of those suffering from central nervous system disorders.
SERVIER OUTRE-MER
Servier is an independent international pharmaceutical company focused on therapeutic progress for patients. They invest significantly in research and development, particularly in oncology, cardiometabolism, and neuroscience. Servier is known for its long-term vision and commitment to patients' needs.